Franklin Biotechnology Discovery’s veteran managers and strong recent results inspire some confidence, but limited research support and an undifferentiated process limit its appeal.
Franklin Biotechnology Discovery Fund Class R6 FRBRX
- NAV / 1-Day Return $191.38 / −1.54 %
- Fund Size $1.1B
- Adjusted Expense Ratio 0.670%
- Net Expense Ratio 0.670%
- Fee Level: Distribution Low
- Share Class Type Retirement, Large
- Morningstar Category Health
- Equity Style Box (Funds) Mid Growth
- Minimum Initial Investment $1M
- Investment Status Open
- TTM Yield 1.84%
- Turnover Ratio 38%
Morningstar’s Analysis FRBRX
Will FRBRX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 37.9
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Jazz Pharmaceuticals PLC | 5.01 | 57M | Healthcare |
Amgen Inc | 4.72 | 54M | Healthcare |
Gilead Sciences Inc | 4.49 | 51M | Healthcare |
argenx SE ADR | 4.14 | 47M | Healthcare |
Vertex Pharmaceuticals Inc | 3.95 | 45M | Healthcare |
Regeneron Pharmaceuticals Inc | 3.81 | 43M | Healthcare |
Revolution Medicines Inc Ordinary Shares | 3.35 | 38M | Healthcare |
Guardant Health Inc | 3.01 | 34M | Healthcare |
AstraZeneca PLC | 2.90 | 33M | Healthcare |
BridgeBio Pharma Inc | 2.52 | 29M | Healthcare |
United States